+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Assessing the risk of false positive serum galactomannan among patients receiving piperacillin/tazobactam for febrile neutropenia

Assessing the risk of false positive serum galactomannan among patients receiving piperacillin/tazobactam for febrile neutropenia

Medical Mycology 55(5): 535-540

Galactomannan (GM) assay is commonly used as an early diagnostic tool for invasive fungal infection (IFI) in high-risk hematology patients. False positivity is frequently observed in GM with the use of piperacillin/tazobactam. The usage of generic drugs over the original brand has a significant cost advantage. The aim of this study was to assess the performance of GM test among patients receiving original and generic piperacillin/tazobactam formulations. The study included 85 adult patients; 62.4% were male with hematological malignancy currently receiving piperacillin/tazobactam. The study group was divided into two groups: patients receiving original and generic piperacillin/tazobactam. Serum GM index was positive in one of 35 patients receiving original piperacillin/tazobactam, whereas it was positive in 46 out of 50 patients receiving generic piperacillin/tazobactam (P < .001). However, the patients receiving generic piperacillin/tazobactam underwent computed tomography (CT) scans more frequently than those receiving original piperacillin/tazobactam (P = .047). In addition, in vitro analysis of GM was performed in two generics and one original piperacillin/tazobactam vials. One generic piperacillin/tazobactam vial included high GM level. False positivity of serum GM with generic formulations of piperacillin/tazobactam is still an ongoing issue in hematology patients. A high rate of serum GM index false positivity may unexpectedly lead to a higher rate of CT scan. Selected piperacillin/tazobactam vials in each batch should be checked for GM to identify a false positivity of GM before purchase.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 057239953

Download citation: RISBibTeXText

PMID: 27915301

DOI: 10.1093/mmy/myw129

Related references

False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clinical Infectious Diseases 38(6): 913-916, 2004

Reduction in false-positive Aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States. Journal of Clinical Microbiology 52(6): 2199-2201, 2015

False positive galactomannan results in adult hematological patients treated with piperacillin-tazobactam. Revista Iberoamericana de Micologia 24(2): 106-112, 2007

False positive galactomannan Platelia due to piperacillin-tazobactam. Medecine et Maladies Infectieuses 42(1): 10-14, 2012

Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clinical Infectious Diseases 38(6): 917-920, 2004

Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia. Pediatric Hematology and Oncology 28(4): 311-320, 2011

False-positive results in the galactomannan Platelia™ Aspergillus assay with generic piperacillin/tazobactam. Revista Iberoamericana de Micologia 2019, 2019

Piperacillin/tazobactam (Tazocin™) seems to be no longer responsible for false-positive results of the galactomannan assay. Journal of Antimicrobial ChemoTherapy 67(7): 1746-1748, 2012

A prospective randomized trial comparing the efficacy and safety of piperacillin/tazobactam versus piperacillin/tazobactam plus netilmicin in the treatment of febrile neutropenia in allogeneic stem cell recipients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 267, 2001

Risk factors for piperacillin/tazobactam-resistant Gram-negative infection in hematology/oncology patients with febrile neutropenia. Supportive Care in Cancer 23(8): 2287-2295, 2015

Lack of evidence that false-positive Aspergillus galactomannan antigen test results are due to treatment with piperacillin-tazobactam. Clinical Infectious Diseases 39(9): 1401-2; Author Reply 1402-3, 2004

Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-risk febrile neutropenia cases. International Journal of Clinical Practice 68(2): 230-235, 2015

Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. Journal of Clinical Oncology 32(14): 1463-1471, 2014

Kinetics of galactomannan in surgical patients receiving perioperative piperacillin/tazobactam prophylaxis. Journal of Antimicrobial ChemoTherapy 58(4): 806-810, 2006

Generic piperacillin/tazobactam is not associated with galactomannan false-positivity in adult patients with cancer: a case-control study. European Journal of Clinical Microbiology and Infectious Diseases 34(7): 1437-1441, 2016